ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Gland Pharma is acquiring Gland Pharma USA Inc. for ₹4.81 Crore to streamline its corporate structure by making it a direct wholly-owned subsidiary.
Gland Pharma approved acquiring its step-down subsidiary, Gland Pharma USA Inc., from another wholly-owned subsidiary to streamline corporate structure. The transaction costs USD 5,01,208.
Gland Pharma Limited granted 5,90,249 employee stock options to 124 employees under its ESOP 2025 scheme. These options are subject to specified vesting schedules and pricing.
Gland Pharma paid fines totaling ₹1.40 Lakh to NSE and BSE for a technical regulatory non-compliance breach. The company has since ensured compliance with shareholder approval.
Fosun Pharma Industrial Pte. Ltd., a promoter, sold 98,97,000 Gland Pharma shares in the open market. Its stake fell from 51.76% to 45.76%.
Gland Pharma reported strong Q1FY27 results with 20% revenue growth and 47% PAT growth. Management highlighted a major strategic CDMO contract and raised long-term CAGR outlook to 20% following recent business wins.
Gland Pharma reports a strong start to FY27, driven by CDMO and B2B growth, though currency shifts significantly impacted the bottom line compared to the previous quarter.
Gland Pharma reported Q1FY27 revenue of ₹18,003 Mn (20% YoY) with PAT of ₹3,170 Mn (47% YoY). Growth was driven by CDMO product launches and B2B volume expansion in US and Europe.
Gland Pharma Ltd reported revenue from operations of ₹1,800 Cr (+19.6% YoY) and net profit of ₹317 Cr (+47.1% YoY) for Q1 FY27.
Gland Pharma reported record quarterly revenue of INR 17,428M (+22% YoY) for Q4FY26, driven by CDMO growth and the Cenexi turnaround. FY26 adjusted PAT reached INR 10,455M with a 16% margin.
Gland Pharma reports a recovery quarter with consolidated revenue up 7% and a sharp 39% EBITDA jump, primarily driven by Cenexi reaching EBITDA break-even and lower raw material costs.
Gland Pharma reports strong FY26 performance with 14% revenue growth and 50% Adj. PAT growth, driven by US market gains and Cenexi recovery.
Gland Pharma Ltd reported revenue from operations of ₹1,743 Cr (+22.3% YoY) and net profit of ₹366.7 Cr (+96.6% YoY) for Q4 FY26.